Dr. Julie Brahmer, Johns Hopkins University, discusses immunotherapies for NSCLC and SCLC, analyzes the relevant trial data and addresses the unique side effects of these therapies. cancergrace.org...
That's a great analysis on the previously available immunotherapies. Immune checkpoints have been targeted for quite a while and new progress has been in recent one year after the vedio has been posted.
